Tagged with RMAC

Pharma Efrén Ocampo, CEO of the Mexican pharmaceutical group Neolpharma, details the strategic thinking that has fostered the emergence of one of the most prominent healthcare groups in Mexico and the challenges and opportunities that lie ahead in Mexico and abroad. Neolpharma Group encompasses five manufacturing companies and 14 other service…

Ireland Barry Heavey, Head of Life Sciences at IDA Ireland, Ireland’s inward investment promotion agency, discusses IDA’s focus on acting as a catalyst for B2B collaboration in converging industries like connective health solutions and innovative drug delivery devices, their focus on advanced manufacturing, and his mission to make IDA Ireland the…

Pharma Tuomo Pätsi, President of the EMEA region for Celgene, talks about marking the tenth anniversary of Switzerland as Celgene´s EMEA headquarters; reveals how their workforce has increased from a handful of individuals in 2006 to 700 in Switzerland and 2,300 across Europe today; and how Celgene’s continuous R&D investment distinguishes…

Pharma Hetero, the global API leader, has consolidated its position as the partner of choice of the pharmaceutical industry in Mexico, with a portfolio of more than 300 APIs. GM Gurulinga Konanuris is piloting entry into the B2C market, with upcoming launches of biosimilars, oncology and HIV treatments. Hetero is also investing…

Pharma President of K8 Global and Senior Advisor to McKinsey, Jean-Luc Butel, explains the major healthcare trends impacting the Asia Pacific region and stresses the need for companies to disrupt current business models in order to effectively tackle the region’s growing burden of unmet needs. You have held several positions in…

Pharma Lundbeck Mexico GM Oscar Parra discusses raising awareness of depression in Mexico, Lundbeck’s innovative treatments for depression and Alzheimer’s, and managing to navigate the country’s regulatory process to ultimately benefit the patient. Lifestyle related illnesses are a major problem in Mexico, with 13 million people suffering from diabetes and 71…

Pharma Dr. Leisha Daly, Janssen Ireland country director and president of the Irish Pharmaceutical Healthcare Association (IPHA) discusses her presidency and the conclusion of a four-year agreement between IPHA and the Irish government on the supply of medicine. She then highlights Janssen’s leadership in Ireland in terms of ‘open-innovation’ and ‘beyond-the-pill’…

Hungary Hungary’s medicinal biotech companies are clustered in the country’s four major university towns: Budapest, Debrecen, Szeged and Pécs, with the majority basing themselves in the capital, Budapest. Click here to read more articles and interviews from Hungary

Pharma Daniel Breitenstein, VP and GM of GSK Switzerland, discusses the benefits of GSK’s three-part transaction with Novartis; the importance of respiratory diseases and vaccines for future success; and how the company has changed its business model by no longer paying for physicians to speak on their behalf, setting in process…

Pharma Janssen Switzerland’s Ludo Ooms highlights the strengths of the Swiss healthcare and life sciences sector including the efficiency of the government, a productive and well trained workforce, the national pricing system, and the climate for innovation; all factors which make Switzerland a strategic market for Johnson & Johnson and Janssen.…

Pharma This map shows the overall contribution of the pharmaceutical industry to the French economy, including number of employees by region, investment stats, and information on private sector research. Click here to download the latest free pharma report on France.

Pharma Singapore, though conscious of its limitations, has been able to leverage its key assets of location, infrastructure and local talent in order to become the business hub for the entire region, with pharma and biotech as key components in its success. Singapore is … an attractive investment destination, especially for the…